Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to improve accessibility to tofersen.

The Government recognises how important it is that patients with motor neurone disease are able to benefit from access to new clinically and cost-effective treatments. The National Institute for Health and Care Excellence (NICE) is currently evaluating tofersen, a new licensed treatment for SOD-1 motor neurone disease, and the company is expected to make an evidence submission to support the appraisal in early June 2026.

NHS England will explore whether an interim commercial agreement could be supported through the Innovative Medicines Fund should NICE issue a positive draft recommendation for tofersen. This would enable eligible patients to benefit from the treatment several months earlier than would otherwise be the case.